Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Methotrexate as an Adjuvant in Severe Thyroid Eye Disease: Does It Really Work as a Steroid-Sparing Agent?

Yong KL, Chng CL, Ming Sie N, Lang S, Yang M, Looi A, Choo CT, Shen S, Seah LL.

Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug;35(4):369-373. doi: 10.1097/IOP.0000000000001279.

PMID:
30624412
2.

Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.

Chan EHL, De-Silva D, Lin AHF, Rabin N, Wechalekar A, Popat R, Chng WJ, Yong KL.

Br J Haematol. 2019 Jul;186(1):162-165. doi: 10.1111/bjh.15743. Epub 2018 Dec 28. No abstract available.

PMID:
30592025
3.

Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.

Cohen OC, Counsell N, Rabin N, Popat R, Owen RG, Popova B, Schofield O, Clifton-Hadley L, Lyons-Lewis J, Rawstron A, Spence C, de Tute RM, Hughes D, Moore S, Smith P, Yong KL.

Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20. No abstract available.

PMID:
30460696
4.

Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.

Pihan M, Keddie S, D'Sa S, Church AJ, Yong KL, Reilly MM, Lunn MP.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 15;5(5):e486. doi: 10.1212/NXI.0000000000000486. eCollection 2018 Sep.

5.

Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.

El-Sharkawi D, Ng CH, Payne EM, Yong KL, Ardeshna KM, Khwaja A, Townsend W, Popat R.

Br J Haematol. 2019 Apr;185(2):344-347. doi: 10.1111/bjh.15457. Epub 2018 Jul 5. No abstract available.

PMID:
29978458
6.

More convenient proteasome inhibition for improved outcomes.

Auner HW, Yong KL.

Lancet Oncol. 2018 Jul;19(7):856-858. doi: 10.1016/S1470-2045(18)30411-X. Epub 2018 Jun 1. No abstract available.

7.

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.

Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL.

Blood Cancer J. 2017 Sep 15;7(9):e610. doi: 10.1038/bcj.2017.76. No abstract available.

8.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H.

Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24.

9.

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.

Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-Justo M, Yong KL.

Br J Haematol. 2016 Sep;174(6):911-22. doi: 10.1111/bjh.14145. Epub 2016 Jun 17.

PMID:
27313079
10.

Cost Minimization Analysis of Precut Cornea Grafts in Descemet Stripping Automated Endothelial Keratoplasty.

Yong KL, Nguyen HV, Cajucom-Uy HY, Foo V, Tan D, Finkelstein EA, Mehta JS.

Medicine (Baltimore). 2016 Feb;95(8):e2887. doi: 10.1097/MD.0000000000002887.

11.

Impact and risk factors of post-stroke bone fracture.

Huo K, Hashim SI, Yong KL, Su H, Qu QM.

World J Exp Med. 2016 Feb 20;6(1):1-8. doi: 10.5493/wjem.v6.i1.1. eCollection 2016 Feb 20.

12.

"Walk the Rim, Feel the Bone" Technique in Superior Sulcus Filling.

Looi AL, Yong KL.

Plast Reconstr Surg Glob Open. 2016 Jan 7;3(12):e592. doi: 10.1097/GOX.0000000000000517. eCollection 2015 Dec.

13.

Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.

Kassen D, Lath D, Lach A, Evans H, Chantry A, Rabin N, Croucher P, Yong KL.

Br J Haematol. 2016 Jan;172(1):64-79. doi: 10.1111/bjh.13790. Epub 2015 Nov 2.

PMID:
26767468
14.

Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease.

Yong KL, Chng CL, Htoon HM, Lim LH, Seah LL.

Int J Endocrinol. 2015;2015:457123. doi: 10.1155/2015/457123. Epub 2015 Nov 22.

15.

Myopia in asian subjects with primary angle closure: implications for glaucoma trends in East Asia.

Yong KL, Gong T, Nongpiur ME, How AC, Lee HK, Cheng L, Perera SA, Aung T.

Ophthalmology. 2014 Aug;121(8):1566-71. doi: 10.1016/j.ophtha.2014.02.006. Epub 2014 Mar 25.

PMID:
24679835
16.

A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors.

Groeneveldt L, Mein G, Garrod R, Jewell AP, Van Someren K, Stephens R, D'Sa SP, Yong KL.

BMC Cancer. 2013 Jan 24;13:31. doi: 10.1186/1471-2407-13-31.

17.

Development of human cells with RXFP1 knockdown using retroviral delivery of microRNA against human RXFP1.

Yong KL, Callander GE, Bergin R, Samuel CS, Bathgate RA.

Ital J Anat Embryol. 2013;118(1 Suppl):10-2.

PMID:
24640558
18.

Improved neurologically intact survival with the use of an automated, load-distributing band chest compression device for cardiac arrest presenting to the emergency department.

Hock Ong ME, Fook-Chong S, Annathurai A, Ang SH, Tiah L, Yong KL, Koh ZX, Yap S, Sultana P.

Crit Care. 2012 Aug 3;16(4):R144. doi: 10.1186/cc11456.

19.

Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations.

Glassford J, Kassen D, Quinn J, Stengel C, Kallinikou K, Khwaja A, Yong KL.

Blood Cancer J. 2012 Jan;2(1):e50. doi: 10.1038/bcj.2011.44. Epub 2012 Jan 13.

20.

Engraftment defect of cytokine-cultured adult human mobilized CD34(+) cells is related to reduced adhesion to bone marrow niche elements.

Kallinikou K, Anjos-Afonso F, Blundell MP, Ings SJ, Watts MJ, Thrasher AJ, Linch DC, Bonnet D, Yong KL.

Br J Haematol. 2012 Sep;158(6):778-87. doi: 10.1111/j.1365-2141.2012.09219.x. Epub 2012 Jul 23.

PMID:
22816563
21.

Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma.

Rabin N, Percy L, Khan I, Quinn J, D'Sa S, Yong KL.

Br J Haematol. 2012 Aug;158(4):499-505. doi: 10.1111/j.1365-2141.2012.09188.x. Epub 2012 Jun 19.

PMID:
22712536
22.

Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma.

Percy LA, Moore SE, Qian W, Dorman J, Rabin N, Watts M, Linch DC, Yong KL.

Br J Haematol. 2012 May;157(4):494-6. doi: 10.1111/j.1365-2141.2011.09023.x. Epub 2012 Jan 16. No abstract available.

PMID:
22512342
23.

Bortezomib-induced inflammatory neuropathy.

Saifee TA, Elliott KJ, Rabin N, Yong KL, D'Sa S, Brandner S, Lunn MP, Blake J, Reilly MM.

J Peripher Nerv Syst. 2010 Dec;15(4):366-8. doi: 10.1111/j.1529-8027.2010.00287.x. No abstract available. Erratum in: J Peripher Nerv Syst. 2011 Mar;16(1):74.

PMID:
21199108
24.

Cardiopulmonary resuscitation interruptions with use of a load-distributing band device during emergency department cardiac arrest.

Ong ME, Annathurai A, Shahidah A, Leong BS, Ong VY, Tiah L, Ang SH, Yong KL, Sultana P.

Ann Emerg Med. 2010 Sep;56(3):233-41. doi: 10.1016/j.annemergmed.2010.01.004. Epub 2010 Mar 12.

PMID:
20138401
25.

Temporal variation of out-of-hospital cardiac arrests in an equatorial climate.

Ong ME, Ng FS, Yap S, Yong KL, Peberdy MA, Ornato JP.

Open Access Emerg Med. 2010 Apr 13;2:37-43. eCollection 2010.

26.

Slow rise of intracellular Ca(2+) concentration in rat primary sensory neurons triggered by loureirin B.

Yang YN, Chen JX, Pang XY, Terakawa S, Chen X, Ji YH, Yong KL.

Sheng Li Xue Bao. 2009 Apr 25;61(2):115-20.

27.

Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells.

Baou M, Jewell A, Muthurania A, Wickremasinghe RG, Yong KL, Carr R, Marsh P, Murphy JJ.

Leukemia. 2009 May;23(5):986-9. doi: 10.1038/leu.2008.340. Epub 2008 Dec 18. No abstract available.

PMID:
19092855
28.

A new dihydrochalcone from dragon's blood, red resin of Dracaena cochinchinensis.

Yong KL, Lv JC, Zhang TB, Xu LR, Chen X.

Nat Prod Res. 2008 Dec;22(18):1624-6. doi: 10.1080/14786410701869341.

PMID:
19085419
29.

Antidiabetic effect of an active fraction extracted from dragon's blood (Dracaena Cochinchinensis).

Gu HJ, Lv JC, Yong KL, Chen X, Liu PP, Zhang XB.

J Enzyme Inhib Med Chem. 2009 Feb;24(1):136-9. doi: 10.1080/14756360801936399 .

PMID:
18618319
30.

Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.

Glassford J, Rabin N, Lam EW, Yong KL.

Br J Haematol. 2007 Oct;139(2):243-54.

PMID:
17897300
31.

A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.

Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, Singh N, Glassford J, Otsuki T, Nathwani AC, Croucher PI, Yong KL.

Leukemia. 2007 Oct;21(10):2181-91. Epub 2007 Jul 26.

PMID:
17657224
32.

[A novel binary vector to get marker-free transgenic plant].

Li X, Weng HB, Han SY, Xi Y, Yong KL.

Sheng Wu Gong Cheng Xue Bao. 2006 Jul;22(4):550-4. Chinese.

PMID:
16894886
33.
34.
35.

An intelligent tutoring system for trauma management (Trauma-Teach): a preliminary report.

Ong LS, Vijayan A, Koh CS, Lai CC, Lim CW, Loke WF, Low SH, Tang KY, Wong FL, Yong KL.

Ann Acad Med Singapore. 2005 Sep;34(8):499-504.

36.
37.

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B, Yong KL.

Clin Cancer Res. 2005 May 1;11(9):3377-84.

39.

Maturation of DC is associated with changes in motile characteristics and adherence.

Burns S, Hardy SJ, Buddle J, Yong KL, Jones GE, Thrasher AJ.

Cell Motil Cytoskeleton. 2004 Feb;57(2):118-32.

PMID:
14691951
40.

Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model.

Ahmed F, Ings SJ, Pizzey AR, Blundell MP, Thrasher AJ, Ye HT, Fahey A, Linch DC, Yong KL.

Blood. 2004 Mar 15;103(6):2079-87. Epub 2003 Nov 20.

PMID:
14630817
41.

Transendothelial migration confers a survival advantage to activated T lymphocytes: role of LFA-1/ICAM-1 interactions.

Borthwick NJ, Akbar AA, Buckley C, Pilling D, Salmon M, Jewell AP, Yong KL.

Clin Exp Immunol. 2003 Nov;134(2):246-52.

42.

Influence of cell cycling and cell division on transendothelial migration of CD34+ cells.

Yong KL, Fahey A, Pizzey A, Linch DC.

Br J Haematol. 2002 Nov;119(2):500-9.

PMID:
12406093
43.

Fetal haemopoietic cells display enhanced migration across endothelium.

Yong KL, Fahey A, Pahal G, Linch DC, Pizzey A, Thomas NS, Jauniaux E, Kinnon C, Thrasher AJ.

Br J Haematol. 2002 Feb;116(2):392-400.

PMID:
11841444
44.

Interleukin 10 regulates cellular responses in monocyte/endothelial cell co-cultures.

Noble KE, Harkness D, Yong KL.

Br J Haematol. 2000 Mar;108(3):497-504.

PMID:
10759705
45.

Monocytes stimulate expression of the Bcl-2 family member, A1, in endothelial cells and confer protection against apoptosis.

Noble KE, Wickremasinghe RG, DeCornet C, Panayiotidis P, Yong KL.

J Immunol. 1999 Feb 1;162(3):1376-83.

47.
48.

Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration.

Craigen JL, Yong KL, Jordan NJ, MacCormac LP, Westwick J, Akbar AN, Grundy JE.

Immunology. 1997 Sep;92(1):138-45.

49.

Selective migration of highly differentiated primed T cells across human umbilical vein endothelial cells.

Borthwick NJ, Akbar AN, MacCormac LP, Salmon M, Yong KL.

Biochem Soc Trans. 1997 May;25(2):258S. No abstract available.

PMID:
9191302
50.

Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration.

Borthwick NJ, Akbar AN, MacCormac LP, Lowdell M, Craigen JL, Hassan I, Grundy JE, Salmon M, Yong KL.

Immunology. 1997 Feb;90(2):272-80.

Supplemental Content

Support Center